YEM Search

搜索结果

靶点ID:TCMBANKGE001495

靶点别名:GDIA1; HEL-S-47e; NPHS8; RHOGDI; RHOGDI-1

靶点描述:Rho GDP dissociation inhibitor alpha

染色体:17

染色体位置:17q25.3

靶点类型:protein-coding

HERB_ID:-

HGNC_Link:678

OMIM_Link:601925

Ensembl_Link:ENSG00000141522

靶点对应的植物

ID	拉丁名	药名	药用植物名	功能与主治	来源	药用部位	使用民族

靶点对应的化合物

化合物ID	化合物名	别名	分子式	分子质量	Smiles

TCMBANKIN033702	citric acid	InChI=1/C6H8O7/c7-3(8)1-6(13,5(11)12)2-4(9)10/h13H,1-2H2,(H,7,8)(H,9,10)(H,11,12; NCGC00090954-02; NCGC00090954-01; HSDB 911; CIT; Citric acid (8CI); BRN 0782061; NCIStruc2_000099; 27109_RIEDEL; AIDS-017733; 1,2,3-PROPANETRICARBOXYLIC ACID,2-HYDROXY (CITRIC ACID); citr; 27488_FLUKA; FEMA No. 2306; E 330; 27485_FLUKA; 27487_FLUKA; 77-92-9; C2404_SIGMA; 2-Hydroxytricarballylic acid; NCIOpen2_004502; F 0001 (polycarboxylic acid); EPA Pesticide Chemical Code 021801; AI3-06286; 245654-34-6; 1,2,3-Propanetricarboxylic acid, 2-hydroxy-; Citretten; Kyselina citronova; 2-hydroxypropane-1,2,3-tricarboxylic acid; Anhydrous citric acid; Citrate standard for IC; C83155_SIAL; LS-2418; WLN: QV1XQVQ1VQ; 1,2,3-Propanetricarboxylic acid, 2-hydroxy- (9CI); NSC30279; .beta.-Hydroxytricarballylic acid; NSC 626579; FLC; NCI60_022579; LS-3185; 2-hydroxy-1,2,3-propanetricarboxylic acid; Caswell No. 221C; EINECS 201-069-1; 43136-35-2; 251275_SIAL; 38730_FLUKA; C4540_SIGMA; FEMA Number 2306; 4-03-00-01272 (Beilstein Handbook Reference); 3-Carboxy-3-hydroxypentane-1,5-dioic acid; Citric acid anhydrous (JAN); C00158; 12262-73-6; 240621_ALDRICH; AIDS017733; MLS001066346; Kyselina 2-hydroxy-1,2,3-propantrikarbonova [Czech]; 2-Hydroxypropanetricarboxylic acid; CCRIS 3292; KBio3_002740; NSC626579; D00037; SBB008922; Kyselina citronova [Czech]; Aciletten; NSC 30279; Anhydrous citric acid (JP15); 46933_SUPELCO; NCIOpen2_004062; Citric acid solution; CHEBI:30769; Citro; BSPBio_003240; NCIStruc1_000057; Uro-trainer; Citric acid, anhydrous (USP); W230618_ALDRICH; Citric acid [USAN:JAN]; H3cit; Chemfill; Hydrocerol A; Suby G; Oprea1_502996; Citric acid, anhydrous; SMR000471840; Citric acid anhydrous; Spectrum3_001850	C6H8O7	192.12	C(C(=O)O)C(CC(=O)O)(C(=O)O)O
TCMBANKIN057911	se	selenium	H2Se	78.97 g/mol	[Se]
TCMBANKIN058229	daidzein	Daidzei; 486-66-8; AIDS-059333; ST057515; KBio2_005871; CCRIS 7600; 7-Hydroxy-3-(4-hydroxy- phenyl)- chromone; SPBio_000205; AIDS059333; 4′,7-Dihydroxy- iso- flavone; nchembio.2007.28-comp31; KBio2_003303; Spectrum3_000191; Isoflavone, 4',7-dihydroxy- (8CI); Oprea1_182317; 7-hydroxy-3-(4-hydroxyphenyl)chromen-4-one; Spectrum5_000857; NCGC00025156-01; BiomolKI_000060; S00273; NCGC00015365-01; KBio1_001023; BiomolKI2_000066; KBioSS_000735; Daidzeol; SMP1_000089; 7,4'-Dihydroxyisoflavone; 7-Hydroxy-3-(4-hydroxyphenyl)-4-benzopyrone; C10208; SPECTRUM200789; nchembio.76-comp16; BSPBio_001741; NCGC00025156-09; Daidzein (6CI); 4H-1-Benzopyran-4-one, 7-hydroxy-3-(4-hydroxyphenyl)-; BRN 0231523; 5-18-04-00089 (Beilstein Handbook Reference); Daidzein; Daidzein (4',7-Dihydroxyisoflavone); KBioGR_002432; NINDS_001023; KBio2_000735; ACon1_000543; NCGC00025156-07; ZINC00047551; daidzein ; NCGC00025156-02; Lopac-D-7802; Tocris-1417; 7-hydroxy-3-(4-hydroxyphenyl)chromone; ACon0_001477; 7-Hydroxy-3-(4-hydroxy-phenyl)-chromone; KBio3_001241; DivK1c_001023; Spectrum4_001964; K 251b; UPCMLD-DP052:001; IDI1_001023; MEGxm0_000123; Lopac0_000412; D7802_SIGMA; Spectrum2_000053; EINECS 207-635-4; Spectrum_000255; 4′,7-Dihydroxyisoflavone; NCGC00025156-05; 4',7-Dihydroxy-iso-flavone; NCGC00025156-04; 7-hydroxy-3-(4-hydroxyphenyl)-4H-chromen-4-one; 7-Hydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; 7-hydroxy-3-(4-hydroxyphenyl)-4-chromenone; 7-Hydroxy-3-(4-hydroxy- phenyl)-4H-1-benzo- pyran-4-one; EU-0100412; CHEBI:28197; SDCCGMLS-0066422.P001; 4',7-Dihydroxyisoflavone; Oprea1_305345	C15H10O4	254.24	C1=CC(=CC=C1C2=COC3=C(C2=O)C=CC(=C3)O)O
TCMBANKIN059684	Vitamin E β-		C29H50O2	430.79	CC1=C(C(=C2CCC(OC2=C1C)(C)CCCC(C)CCCC(C)CCCC(C)C)C)O
TCMBANKIN059746	α-tocopherol		C29H50O2	430.7 g/mol	CC1=C(C2=C(CCC(O2)(C)CCCC(C)CCCC(C)CCCC(C)C)C(=C1O)C)C
TCMBANKIN060110	oestrone		C18H22O2	270.4 g/mol	CC12CCC3C(C1CCC2=O)CCC4=C3C=CC(=C4)O
TCMBANKIN060889	delta(9)-tetrahydrocannabinol		C21H30O2	314.5 g/mol	CCCCCC1=CC(=C2C3C=C(CCC3C(OC2=C1)(C)C)C)O
TCMBANKIN060892	tetrahydrocannabinol delta8				CCCCCC1=CC2=C(C3C=C(CCC3C(O2)(C)C)C)C(=C1)O

靶点对应的疾病

疾病ID	疾病名	MeSH名	HPO名	UMLS名	疾病类型

TCMBANKDI000009		Neoplasms	Abnormality of the nervous system; Neoplasm	Neoplastic Process	disease
TCMBANKDI000166		-	-	Neoplastic Process	disease
TCMBANKDI002512		Digestive System Diseases	Abnormality of the digestive system; Abnormality of the immune system	Disease or Syndrome	disease
TCMBANKDI002735		Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Nervous System Diseases; Hemic and Lymphatic Diseases	Abnormality of the immune system; Neoplasm; Abnormality of blood and blood-forming tissues	Neoplastic Process	disease
TCMBANKDI004417		Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases	-	Disease or Syndrome	disease
TCMBANKDI004508		Pathological Conditions, Signs and Symptoms; Skin and Connective Tissue Diseases	Abnormality of the integument; Abnormality of connective tissue	Acquired Abnormality	disease
TCMBANKDI007163		Musculoskeletal Diseases; Nervous System Diseases	-	Disease or Syndrome	disease
TCMBANKDI011743		Neoplasms; Skin and Connective Tissue Diseases	Neoplasm; Abnormality of the breast	Neoplastic Process	group
TCMBANKDI012932		Infections; Immune System Diseases	-	Disease or Syndrome	group
TCMBANKDI013453		Pathological Conditions, Signs and Symptoms; Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases	Abnormality of metabolism/homeostasis; Abnormality of the genitourinary system	Finding	phenotype
TCMBANKDI016050		Neoplasms; Skin and Connective Tissue Diseases	-	Neoplastic Process	disease
TCMBANKDI017642		Neoplasms	Abnormality of the integument; Neoplasm	Neoplastic Process	disease
TCMBANKDI021045		-	-	Finding	phenotype
TCMBANKDI030938		-	-	Finding	phenotype
TCMBANKDI031189		Neoplasms	Neoplasm; Abnormality of the respiratory system	Neoplastic Process	disease